{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:42Z","timestamp":1794047442980,"version":"4.8.0"},"reference-count":29,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with multiple myeloma (MM) who experience early relapse within 12 months of therapy initiation are considered functional high-risk and represent an unmet need, needing better therapies to improve outcomes. The final IKEMA (clinicaltrials gov. identifier: NCT03275285) progression-free survival (PFS) analysis confirmed the significant PFS improvement reported at interim analysis with isatuximab (Isa) plus carfilzomib and dexamethasone (Kd; Isa-Kd) versus Kd in patients with relapsed MM (updated median PFS: 35.7 vs. 19.2 months; hazard ratio [HR] =0.58, 95% confidence interval [CI]: 0.42- 0.79). This IKEMA subgroup analysis examined efficacy and safety of Isa-Kd versus Kd in patients who experienced early (n=61 [Isa-Kd], n=46 [Kd]) vs. late relapse (n=104 [Isa-Kd], n=72 [Kd]). As expected, more aggressive features in baseline characteristics were observed in early relapse patients. Consistent with IKEMA overall population results, median PFS (early relapse: 24.7 vs. 17.2 months, HR=0.662, 95% CI: 0.407-1.077; late relapse: 42.7 vs. 21.9 months, HR=0.542, 95% CI: 0.355- 0.826), minimal residual disease negativity (MRD\u2212) (early relapse: 24.6% vs. 15.2%; late relapse: 37.5% vs. 16.7%), and MRD\u2212 complete response (\u2265CR) rates (early relapse: 18.0% vs. 10.9%; late relapse: 30.8% vs. 13.9%) were higher with Isa-Kd versus Kd, respectively, in both early and late relapse patients. Grade \u22653, serious treatment-emergent adverse events, and death rates were higher in the late relapse Isa-Kd arm. However, the numbers of deaths were low and treatment exposure was significantly longer in Isa-Kd versus Kd late relapse patients. These results support the addition of Isa to Kd as standardof- care therapy for relapsed and\/or refractory MM regardless of relapse timing.<\/jats:p>","DOI":"10.3324\/haematol.2023.283073","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T06:47:54Z","timestamp":1692168474000},"page":"604-616","source":"Crossref","is-referenced-by-count":10,"title":["Isatuximab plus carfilzomib and dexamethasone in patients with early &lt;i&gt;versus&lt;\/i&gt; late relapsed multiple myeloma: IKEMA subgroup analysis"],"prefix":"10.3324","volume":"109","author":[{"given":"Thierry","family":"Facon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tekle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Risse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"57693","doi-asserted-by":"crossref","unstructured":"Jagannath S, Abonour R, Durie BGM. Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect MM Registry (2010-2016). Clin Lymphoma Myeloma Leuk. 2018; 18(7):480-485.","DOI":"10.1016\/j.clml.2018.04.007"},{"key":"57694","doi-asserted-by":"crossref","unstructured":"Raab MS, Fink L, Schoen P. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. Br J Haematol. 2019; 185(5):981-984.","DOI":"10.1111\/bjh.15680"},{"key":"57695","doi-asserted-by":"crossref","unstructured":"Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016; 32(1):95-103.","DOI":"10.1185\/03007995.2015.1105202"},{"key":"57696","doi-asserted-by":"crossref","unstructured":"Kumar SK, Therneau TM, Gertz MA. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004; 79(7):867-874.","DOI":"10.4065\/79.7.867"},{"key":"57697","doi-asserted-by":"crossref","unstructured":"Majithia N, Rajkumar SV, Lacy MQ. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016; 30(11):2208-2213.","DOI":"10.1038\/leu.2016.147"},{"key":"57698","doi-asserted-by":"crossref","unstructured":"Soekojo CY, Chung TH, Furqan MS, Chng WJ. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022; 12(1):24.","DOI":"10.1038\/s41408-021-00576-3"},{"key":"57699","doi-asserted-by":"crossref","unstructured":"Kumar S, Mahmood ST, Lacy MQ. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008; 42(6):413-420.","DOI":"10.1038\/bmt.2008.180"},{"key":"57700","doi-asserted-by":"crossref","unstructured":"Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant. 2015; 50(2):204-208.","DOI":"10.1038\/bmt.2014.237"},{"key":"57701","doi-asserted-by":"crossref","unstructured":"Martin TG, Corzo K, Chiron M. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019; 8(12):1522.","DOI":"10.3390\/cells8121522"},{"key":"57702","doi-asserted-by":"crossref","unstructured":"Leleu X, Martin T, Weisel K. Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022; 101(10):2123-2137.","DOI":"10.1007\/s00277-022-04917-5"},{"key":"57703","unstructured":"Sanofi. Sarclisa (isatuximab-irfc) [package insert]. 2021. Publisher Full Text|"},{"key":"57704","doi-asserted-by":"crossref","unstructured":"Jiang H, Acharya C, An G. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016; 30(2):399-408.","DOI":"10.1038\/leu.2015.240"},{"key":"57705","doi-asserted-by":"crossref","unstructured":"Tai YT, Anderson KC. Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget. 2017; 8(68):112166-112167.","DOI":"10.18632\/oncotarget.22992"},{"key":"57706","unstructured":"Sanofi. Sarclisa (isatuximab) [summary of product characteristics]. 2021. Publisher Full Text|"},{"key":"57707","doi-asserted-by":"crossref","unstructured":"Attal M, Richardson PG, Rajkumar SV. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394(10214):2096-2107.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"57708","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MA, Yong K. Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020; 16(2):4347-4358.","DOI":"10.2217\/fon-2019-0431"},{"key":"57709","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MA, Mikhael J. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021; 397(10292):2361-2371.","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"57710","unstructured":"Sanofi. Sarclisa (isatuximab) [Prescribing Information]. 2021. Publisher Full Text|"},{"key":"57711","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MA, Mikhael J. Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM). Ann Oncol. 2022; 33(6):P664-665.","DOI":"10.1016\/j.annonc.2022.04.013"},{"key":"57712","doi-asserted-by":"crossref","unstructured":"Weisel K, Geils G, Karlin L. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of the phase 3 CANDOR study in patients with early or late relapse. Blood. 2020; 136(Suppl 1):S37-38.","DOI":"10.1182\/blood-2020-133908"},{"key":"57713","unstructured":"Terpos E, Caers J, Gamberi B. Response to carfilzomib regimens among patients with early or late relapse following prior multiple myeloma therapy: a subgroup analysis from a prospective observational study across Europe and Israel. 2020."},{"key":"57714","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"57715","doi-asserted-by":"crossref","unstructured":"Finn F, Mac\u00e9 S, Chu R. Development of a Hydrashift 2\/4 isatuximab assay to mitigate interference with monoclonal protein detection on immunofixation electrophoresis in vitro diagnostic tests in multiple myeloma. Blood. 2020; 136(Suppl 1):S15.","DOI":"10.1182\/blood-2020-136613"},{"key":"57716","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 282(53):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"57717","doi-asserted-by":"crossref","unstructured":"Cox D. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972; 34(2):187-202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"57718","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Augustson B. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. 2023; 98(1):E15-E19.","DOI":"10.1002\/ajh.26602"},{"key":"57719","doi-asserted-by":"crossref","unstructured":"Spencer A, Moreau P, Mateos MV. Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy. J Clin Oncol. 2022; 40(Suppl 16):S8052.","DOI":"10.1200\/JCO.2022.40.16_suppl.8052"},{"key":"57720","doi-asserted-by":"crossref","unstructured":"Mateos MV, Goldschmidt H, San-Miguel J. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018; 36(2):463-470.","DOI":"10.1002\/hon.2499"},{"key":"57721","doi-asserted-by":"crossref","unstructured":"Usmani S, Patel K, Kari P. KarMMa-2 Cohort 2a: Efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022; 140(Suppl 1):S875-877.","DOI":"10.1182\/blood-2022-162469"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283073\/76557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283073\/76558","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11204\/75990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:40Z","timestamp":1794045880000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283073","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,17]]}}}